{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T17:40:21Z","timestamp":1791222021622,"version":"4.1.0"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Chemical Biology"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.cbpa.2018.05.018","type":"journal-article","created":{"date-parts":[[2018,6,11]],"date-time":"2018-06-11T06:11:17Z","timestamp":1528697477000},"page":"66-74","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"special_numbering":"C","title":["Therapeutic strategies for targeting neurodegenerative protein misfolding disorders"],"prefix":"10.1016","volume":"44","author":[{"given":"Robert H","family":"Scannevin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cbpa.2018.05.018_bib0005","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/nature19793","article-title":"Evidence for a limit to human lifespan","volume":"538","author":"Dong","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.cbpa.2018.05.018_bib0010","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1007\/s11065-017-9357-1","article-title":"Population base rates and disease course of common psychiatric and neurodegenerative disorders","volume":"27","author":"Kitchen Andren","year":"2017","journal-title":"Neuropsychol Rev"},{"key":"10.1016\/j.cbpa.2018.05.018_bib0015","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1016\/S0140-6736(16)31678-6","article-title":"Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990\u20132015: a systematic analysis for the Global Burden of Disease Study 2015","volume":"388","author":"Disease","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.cbpa.2018.05.018_bib0020","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s12551-017-0353-8","article-title":"Recent progress on understanding the mechanisms of amyloid nucleation","volume":"10","author":"Chatani","year":"2018","journal-title":"Biophys Rev"},{"key":"10.1016\/j.cbpa.2018.05.018_bib0025","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/nature11283","article-title":"A mutation in APP protects against Alzheimer's disease and age-related cognitive decline","volume":"488","author":"Jonsson","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.cbpa.2018.05.018_bib0030","first-page":"7","article-title":"Genetics of beta-amyloid precursor protein in Alzheimer\u2019s disease","author":"Tcw","year":"2017","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.cbpa.2018.05.018_bib0035","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.molmed.2005.02.008","article-title":"Tau phosphorylation in Alzheimer\u2019s disease: pathogen or protector?","volume":"11","author":"Lee","year":"2005","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.cbpa.2018.05.018_bib0040","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1097\/NEN.0b013e31825018f7","article-title":"Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature","volume":"71","author":"Nelson","year":"2012","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.1016\/j.cbpa.2018.05.018_bib0045","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a009282","article-title":"Motor control abnormalities in Parkinson\u2019s disease","volume":"2","author":"Mazzoni","year":"2012","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.cbpa.2018.05.018_bib0050","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1111\/j.1750-3639.2010.00373.x","article-title":"Profile of cognitive impairment in Parkinson\u2019s disease","volume":"20","author":"Watson","year":"2010","journal-title":"Brain Pathology"},{"key":"10.1016\/j.cbpa.2018.05.018_bib0055","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1097\/WCO.0000000000000215","article-title":"alpha-Synuclein and Lewy pathology in Parkinson's disease","volume":"28","author":"Kalia","year":"2015","journal-title":"Curr Opin Neurol"},{"key":"10.1016\/j.cbpa.2018.05.018_bib0060","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1146\/annurev.cellbio.042308.113313","article-title":"alpha-Synuclein: membrane interactions and toxicity in Parkinson's disease","volume":"26","author":"Auluck","year":"2010","journal-title":"Annu Rev Cell Dev Biol"},{"key":"10.1016\/j.cbpa.2018.05.018_bib0065","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.nbd.2017.04.004","article-title":"Alpha-synuclein: pathology, mitochondrial dysfunction and neuroinflammation in Parkinson's disease","volume":"109","author":"Rocha","year":"2018","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.cbpa.2018.05.018_bib0070","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1126\/science.aan6160","article-title":"Structural basis of membrane disruption and cellular toxicity by alpha-synuclein oligomers","volume":"358","author":"Fusco","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.cbpa.2018.05.018_bib0075","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/nrneurol.2011.153","article-title":"Clinical diagnosis and management of amyotrophic lateral sclerosis","volume":"7","author":"Hardiman","year":"2011","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.cbpa.2018.05.018_bib0080","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/ana.21147","article-title":"Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations","volume":"61","author":"Mackenzie","year":"2007","journal-title":"Ann Neurol"},{"key":"10.1016\/j.cbpa.2018.05.018_bib0085","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/ng.132","article-title":"TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis","volume":"40","author":"Kabashi","year":"2008","journal-title":"Nat Genet"},{"key":"10.1016\/j.cbpa.2018.05.018_bib0090","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1126\/science.1165942","article-title":"Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6","volume":"323","author":"Vance","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.cbpa.2018.05.018_bib0095","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.molcel.2018.02.001","article-title":"FUS regulates activity of microRNA-mediated gene silencing","volume":"69","author":"Zhang","year":"2018","journal-title":"Mol Cell"},{"key":"10.1016\/j.cbpa.2018.05.018_bib0100","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/362059a0","article-title":"Mutations in Cu\/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis","volume":"362","author":"Rosen","year":"1993","journal-title":"Nature"},{"key":"10.1016\/j.cbpa.2018.05.018_bib0105","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1080\/14660820050515160","article-title":"New consensus research on neuropathological aspects of familial amyotrophic lateral sclerosis with superoxide dismutase 1 (SOD1) gene mutations: inclusions containing SOD1 in neurons and astrocytes","volume":"1","author":"Kato","year":"2000","journal-title":"Amyotroph Lateral Scler Other Motor Neuron Disord"},{"key":"10.1016\/j.cbpa.2018.05.018_bib0110","doi-asserted-by":"crossref","first-page":"16607","DOI":"10.1073\/pnas.262527099","article-title":"Common denominator of Cu\/Zn superoxide dismutase mutants associated with amyotrophic lateral sclerosis: decreased stability of the apo state","volume":"99","author":"Lindberg","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.cbpa.2018.05.018_bib0115","doi-asserted-by":"crossref","first-page":"7021","DOI":"10.1073\/pnas.1237797100","article-title":"Cu\/Zn superoxide dismutase mutants associated with amyotrophic lateral sclerosis show enhanced formation of aggregates in vitro","volume":"100","author":"Stathopulos","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.cbpa.2018.05.018_bib0120","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1016\/S0140-6736(15)00461-4","article-title":"Frontotemporal dementia","volume":"386","author":"Bang","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.cbpa.2018.05.018_bib0125","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1111\/bpa.12486","article-title":"Frontotemporal lobar degeneration: pathogenesis, pathology and pathways to phenotype","volume":"27","author":"Mann","year":"2017","journal-title":"Brain Pathol"},{"key":"10.1016\/j.cbpa.2018.05.018_bib0130","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.1093\/brain\/awp214","article-title":"A new subtype of frontotemporal lobar degeneration with FUS pathology","volume":"132","author":"Neumann","year":"2009","journal-title":"Brain"},{"key":"10.1016\/j.cbpa.2018.05.018_bib0135","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1097\/WCO.0000000000000116","article-title":"An update on Huntington\u2019s disease: from the gene to the clinic","volume":"27","author":"Kim","year":"2014","journal-title":"Curr Opin Neurol"},{"key":"10.1016\/j.cbpa.2018.05.018_bib0140","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1602\/neurorx.1.2.255","article-title":"Huntington\u2019s disease genetics","volume":"1","author":"Myers","year":"2004","journal-title":"NeuroRx"},{"key":"10.1016\/j.cbpa.2018.05.018_bib0145","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1016\/S0140-6736(03)13304-1","article-title":"Huntingtin aggregation and toxicity in Huntington\u2019s disease","volume":"361","author":"Bates","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.cbpa.2018.05.018_bib0150","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/neup.12355","article-title":"Creutzfeldt-Jakob disease","volume":"37","author":"Iwasaki","year":"2017","journal-title":"Neuropathology"},{"key":"10.1016\/j.cbpa.2018.05.018_bib0155","first-page":"277","article-title":"Chapter Seven\u2014the structure of mammalian prions and their aggregates","volume":"vol 329","author":"V\u00e1zquez-Fern\u00e1ndez","year":"2017"},{"key":"10.1016\/j.cbpa.2018.05.018_bib0160","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1093\/brain\/awx255","article-title":"Presence of tau pathology within foetal neural allografts in patients with Huntington\u2019s and Parkinson\u2019s disease","volume":"140","author":"Cisbani","year":"2017","journal-title":"Brain"},{"key":"10.1016\/j.cbpa.2018.05.018_bib0165","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1093\/jnen\/62.4.389","article-title":"Colocalization of tau and alpha-synuclein epitopes in Lewy bodies","volume":"62","author":"Ishizawa","year":"2003","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.1016\/j.cbpa.2018.05.018_bib0170","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.3233\/JAD-171013","article-title":"A longitudinal study of total and phosphorylated alpha-synuclein with other biomarkers in cerebrospinal fluid of Alzheimer's disease and mild cognitive impairment","volume":"61","author":"Wang","year":"2018","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.cbpa.2018.05.018_bib0175","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s00401-017-1786-7","article-title":"Co-occurrence of mixed proteinopathies in late-stage Huntington\u2019s disease","volume":"135","author":"St-Amour","year":"2018","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.cbpa.2018.05.018_bib0180","doi-asserted-by":"crossref","DOI":"10.1111\/jnc.14327","article-title":"Pathomechanisms of TDP-43 in neurodegeneration","author":"Gao","year":"2018","journal-title":"J Neurochem"},{"key":"10.1016\/j.cbpa.2018.05.018_bib0185","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJMoa1210951","article-title":"A phase 3 trial of semagacestat for treatment of Alzheimer's disease","volume":"369","author":"Doody","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cbpa.2018.05.018_bib0190","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1001\/jamaneurol.2015.0607","article-title":"Targeting prodromal Alzheimer disease with avagacestat: a randomized clinical trial","volume":"72","author":"Coric","year":"2015","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.cbpa.2018.05.018_bib0195","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1124\/jpet.109.152975","article-title":"Begacestat (GSI-953): a novel, selective thiophene sulfonamide inhibitor of amyloid precursor protein gamma-secretase for the treatment of Alzheimer's disease","volume":"331","author":"Martone","year":"2009","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.cbpa.2018.05.018_bib0200","doi-asserted-by":"crossref","first-page":"10435","DOI":"10.1021\/acs.jmedchem.6b00307","article-title":"Discovery of the 3-imino-1,2,4-thiadiazinane-1,1-dioxide derivative verubecestat (MK-8931)-A beta-site amyloid precursor protein cleaving enzyme 1 inhibitor for the treatment of Alzheimer's disease","volume":"59","author":"Scott","year":"2016","journal-title":"J Med Chem"},{"key":"10.1016\/j.cbpa.2018.05.018_sbref0205","doi-asserted-by":"crossref","first-page":"363ra","DOI":"10.1126\/scitranslmed.aad9704","article-title":"The BACE1 inhibitor verubecestat (MK-8931) reduces CNS beta-amyloid in animal models and in Alzheimer's disease patients","volume":"8","author":"Kennedy","year":"2016","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.cbpa.2018.05.018_bib0210","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.ejmech.2018.02.035","article-title":"Secretase inhibitors for the treatment of Alzheimer\u2019s disease: long road ahead","volume":"148","author":"Kumar","year":"2018","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.cbpa.2018.05.018_bib0215","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.neuron.2012.05.009","article-title":"Sustained therapeutic reversal of Huntington's disease by transient repression of huntingtin synthesis","volume":"74","author":"Kordasiewicz","year":"2012","journal-title":"Neuron"},{"key":"10.1016\/j.cbpa.2018.05.018_bib0220","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S1474-4422(13)70061-9","article-title":"An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study","volume":"12","author":"Miller","year":"2013","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.cbpa.2018.05.018_sbref0225","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aag0481","article-title":"Tau reduction prevents neuronal loss and reverses pathological tau deposition and seeding in mice with tauopathy","volume":"9","author":"DeVos","year":"2017","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.cbpa.2018.05.018_bib0230","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.addr.2015.01.008","article-title":"Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides","volume":"87","author":"Geary","year":"2015","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.cbpa.2018.05.018_bib0235","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.bcp.2017.04.004","article-title":"Natural product-based amyloid inhibitors","volume":"139","author":"Velander","year":"2017","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.cbpa.2018.05.018_bib0240","article-title":"The novel alpha-synuclein stabilizer NPT200-11 improves behavior, neuropathology, and Biochemistry in the murine thy1-ASYN transgenic model of Parkinson\u2019s disease","author":"Koike","year":"2014","journal-title":"Neurosci Meeting Planner"},{"key":"10.1016\/j.cbpa.2018.05.018_bib0245","doi-asserted-by":"crossref","first-page":"393","DOI":"10.2174\/1567205014666170116152622","article-title":"Conformation as the Therapeutic Target for Neurodegenerative Diseases","volume":"14","author":"Krishnan","year":"2017","journal-title":"Curr Alzheimer Res"},{"key":"10.1016\/j.cbpa.2018.05.018_sbref0250","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/nature19323","article-title":"The antibody aducanumab reduces Abeta plaques in Alzheimer's disease","volume":"537","author":"Sevigny","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.cbpa.2018.05.018_bib0255","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s13195-017-0318-y","article-title":"A phase III randomized trial of gantenerumab in prodromal Alzheimer's disease","volume":"9","author":"Ostrowitzki","year":"2017","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/j.cbpa.2018.05.018_bib0260","doi-asserted-by":"crossref","first-page":"39374","DOI":"10.1038\/srep39374","article-title":"Structure of crenezumab complex with Abeta shows loss of beta-hairpin","volume":"6","author":"Ultsch","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.cbpa.2018.05.018_bib0265","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s13195-016-0181-2","article-title":"Safety and tolerability of BAN2401\u2014a clinical study in Alzheimer\u2019s disease with a protofibril selective Abeta antibody","volume":"8","author":"Logovinsky","year":"2016","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/j.cbpa.2018.05.018_sbref0270","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1002\/mds.26878","article-title":"First-in-human assessment of PRX002, an anti-alpha-synuclein monoclonal antibody, in healthy volunteers","volume":"32","author":"Schenk","year":"2017","journal-title":"Mov Disord"},{"key":"10.1016\/j.cbpa.2018.05.018_bib0275","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1126\/science.aaa0769","article-title":"Evolution. Systematic humanization of yeast genes reveals conserved functions and genetic modularity","volume":"348","author":"Kachroo","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.cbpa.2018.05.018_bib0280","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.cels.2016.12.011","article-title":"Genome-scale networks link neurodegenerative disease genes to alpha-synuclein through specific molecular pathways","volume":"4","author":"Khurana","year":"2017","journal-title":"Cell Syst"},{"key":"10.1016\/j.cbpa.2018.05.018_sbref0285","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1126\/science.1245296","article-title":"Identification and rescue of alpha-synuclein toxicity in Parkinson patient-derived neurons","volume":"342","author":"Chung","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.cbpa.2018.05.018_sbref0290","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1126\/science.1245321","article-title":"Yeast reveal a ``druggable\" Rsp5\/Nedd4 network that ameliorates alpha-synuclein toxicity in neurons","volume":"342","author":"Tardiff","year":"2013","journal-title":"Science"}],"container-title":["Current Opinion in Chemical Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1367593118300693?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1367593118300693?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T02:39:04Z","timestamp":1761273544000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1367593118300693"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":58,"alternative-id":["S1367593118300693"],"URL":"https:\/\/doi.org\/10.1016\/j.cbpa.2018.05.018","relation":{},"ISSN":["1367-5931"],"issn-type":[{"value":"1367-5931","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic strategies for targeting neurodegenerative protein misfolding disorders","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Chemical Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cbpa.2018.05.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}